Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside

Sadri-Ardekani and Atala
Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside

Hooman Sadri-Ardekani1,2,3* and Anthony Atala1,3

Abstract
Male infertility management has made significant progress during the past three decades, especially after the introduction of intracytoplasmic sperm injection in 1992. However, many boys and men still suffer from primary testicular failure due to acquired or genetic causes. New and novel treatments are needed to address these issues. Spermatogenesis originates from spermatogonial stem cells (SSCs) that reside in the testis. Many of these men lack SSCs or have lost SSCs over time as a result of specific medical conditions or toxic exposures. Loss of SSCs is critical in prepubertal boys who suffer from cancer and are going through gonadotoxic cancer treatments, as there is no option of sperm cryopreservation due to sexual immaturity. The development of SSC transplantation in a mouse model to repopulate spermatozoa in depleted testes has opened new avenues of research in other animal models, including non-human primates. Recent advances in cryopreservation and in vitro propagation of human SSCs offer promise for human SSC autotransplantation in the near future. Ongoing research is focusing on safety and technical issues of human SSC autotransplantation. This is the time to counsel parents and boys at risk of infertility on the possibility of cryopreserving and banking a small amount of testis tissue for potential future use in SSC transplantation.

Introduction
Male infertility is a problem in 7% of all men [1]. In 1696 sperm were first seen under the microscope and called ‘homunculi’ as it was believed that the sperm contained a miniature human [2]. Three centuries later, the development of intracytoplasmic sperm injection (ICSI) into an egg has revolutionized male infertility treatments as part of assisted reproductive technologies (ARTs) [3,4]. However, many men with primary testicular defects in sperm production due to genetic disorders or as a consequence of cancer treatments are still unable to become biological fathers. The identification of rat spermatogonial stem cells (SSCs) in 1971 as the foundation for spermatogenesis and sustaining male fertility [5] and the introduction of SSC transplantation in mice in 1994 opened new avenues for the field of male infertility treatments [6]. Since the discovery of the feasibility of SSC isolation and autotransplantation, it has been demonstrated in several species, including non-human primates [7]. Brian Hermann and colleagues [7] recently demonstrated successful autologous and allogeneic SSC transplantations in adult and prepubertal macaque testes that were previously rendered infertile with alkylating chemotherapy. As a result of these findings, translation of this technology to human studies is expected soon. This review focuses on several areas, including identifying patients that may benefit from testicular tissue banking to preserve SSCs, recent achievements in SSC technology, and concerns that need to be addressed before applying SSC autotransplantation in the clinical setting.

Who may benefit from testicular tissue preservation and future SSC transplantation?

Malignant diseases
Every year in the United States more than 12,000 children and adolescents aged under 20 years are diagnosed with cancer [8]. The overall cure rates of these cancer patients are approaching 80%; therefore, the number of childhood cancer survivors is increasing over time [8].
It is known that either cancer [9] or cancer treatments [10] may adversely affect male reproduction. Chemotherapy and radiotherapy target rapidly dividing cells. These treatments not only eliminate malignant cells, but also affect germ cells. In the testis, spermatogonial cells divide rapidly and are very sensitive to cytotoxic agents, although the less active stem cells may also be killed [10]. Even in prepubescent boys, spermatogonial cells divide [11] and increase in number over time [12]. Thus, cancer treatments may result in temporary, long-term, or permanent gonadal failure in male cancer survivors [10]. In clinical practice, it is important to estimate infertility risk based on cancer type and cancer treatment protocols for each patient and consult with him and his parents (for prepubertal and adolescent patients) on his infertility risk (Tables 1 and 2) [13-15]. In adult men, semen cryopreservation before starting chemotherapy or radiotherapy is clinically approved as an efficient solution to preserve fertility by using ART procedures. Live births have been reported after insemination of stored sperm even after freezing for a period of 28 years [16]. In immature boys, spermatogenesis has not begun; therefore, storing testicular tissue prior to cancer treatments for future SSC autotransplantation could be an option (Figure 1).

Non-malignant diseases need cytotoxic treatments
In addition to malignant diseases, certain benign hematological disorders, such as myelodysplasia, sickle cell disease, aplastic anemia, thalassemia major, and Fanconi anemia, and severe autoimmune diseases unresponsive to immunosuppressive therapy, such as juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, systemic sclerosis and immune cytopenias, necessitate administration of high dose chemotherapy could be an option (Figure 1).

This often leads to severe, dose-dependent and sometimes irreversible spermatogenic damage [20]. Dependent on treatment types (Table 2), these patients may also need to be counseled for fertility preservation.

Klinefelter syndrome
Klinefelter syndrome (KS; 47,XXY) is a progressive testicular failure causing small firm testes, androgen deficiency, and azoospermia [21]. This syndrome has been reported in 1 out of 660 live male births [22] and represents approximately 15% of azoospermia in infertile men [23]. KS cases have normal sexual hormones during childhood and initiate puberty at the same age as normal children; however, around mid-puberty the testes begin to deteriorate with the loss of germ cells [24]. Successful testicular sperm extraction is expected in half of KS patients [24]; a recent study showed 70% success for microscopic testicular sperm extraction in 10 cases where the males were aged between 14 and 22 years [25]. Preserving testicular tissue containing SSCs before puberty may help some KS boys in the future [26]. Less than 10% of KS is diagnosed before puberty [22]; therefore, a cost-effective and easy method (for example, PCR) to screen these children before puberty is needed.

Cryptorchidism
Failure in congenital testicular descent - cryptorchidism - is the most frequent genital abnormality, affecting approximately 1% of mature births [27]. In a study of 89 cryptorchid boys who underwent bilateral testis biopsy during orchiopexy operation, 70% of scrotal testes had an impaired transformation of A dark spermatogonia, indicating that cryptorchidism is a bilateral disease [28]. Up to 20% of boys with unilateral cryptorchidism experience fertility problems and this figure increases up to

Table 1 Estimation of infertility risk in different types of cancer

| High risk (>80%) | Intermediate risk (20-80%) | Low risk (<20%) | Very low/ no risk | Unknown risk |
|------------------|--------------------------|----------------|-------------------|-------------|
| Any cancer requiring bone marrow transplant/ stem cell transplant | Acute myeloblastic leukemia | Acute lymphoblastic leukemia | Thyroid cancer | Chronic myeloid leukemia |
| Brain tumor | Brain tumor | Germ cell tumors (without radiotherapy) | Colon cancer |
| Germ cell tumors | Hepatoblastoma | Nephroblastoma (without abdominal radiotherapy) | Gastrointestinal stromal tumor |
| Hodgkin lymphoma | Hodgkin lymphoma | Retinoblastoma | Head and neck cancer |
| Neuroblastoma | Neuroblastoma | Testicular cancer | Non-small cell lung cancer |
| Nephroblastoma | Non-Hodgkin lymphoma | Wilms’ tumor | Pancreatic cancer |
| Non-Hodgkin lymphoma | Sarcoma | Testicular cancer |
| Sarcoma | Testicular cancer |
| Testicular cancer | Wilms’ tumor |
70% for boys with bilateral cryptorchidism [29]. Paternity rate decreases significantly in corrected bilateral cryptorchidism (65%) compared with unilateral cryptorchidism (89.7%) and control men (93.2%) [30]. Because of gradual diminishing germ cell number in these patients, it may be an option to store a portion of the testis biopsy, which can be harvested during the orchiopexy operation [31,32].

**Testicular tissue biopsy and cryopreservation**

Testicular biopsy is an open surgical procedure and needs to be performed under general anesthesia in children. Retrieving tissue from only one testis is suggested to minimize manipulation [14] and the size of tissue may vary between 80 and 250 mm³ based on testicular size in the different age groups [33]. To minimize the risk of general anesthesia, this process should be performed at the same time as other clinical procedures (for example, bone marrow biopsy, central line replacement or orchiopexy) when possible. Based on our [34] and other groups’ experiences [14,35] no major surgical complications occurred during or after testicular biopsy. Long-term follow-up of cryptorchid boys who had undergone testicular biopsy during orchiopexy showed no negative effects such as producing anti-sperm antibody or testicular scars [32]. Onset of sperm production (spermarche) is an early pubertal event. The median age of spermarche is estimated to be around 13 to 14 years, with a range between 11 and 17 years [36,37]. Thus, we recommend searching for testicular sperm in specimens from all boys aged 10 years or older, since freezing testicular sperm in glycerol-based medium [38] for use in

### Table 2 Estimation of infertility risk using different types of cytotoxic treatments

| High risk (>80%)                                                                 | Intermediate risk (20-80%)                                                                 | Low risk (<20%)                                                                 | Very low/ no risk |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------|
| Any alkylating agent plus total body irradiation, pelvic radiation, or testicular radiation (for example, procarbazine, nitrogen mustard, cyclophosphamide) | BEP × 2–4 cycles (bleomycin, etoposide, cisplatin)                                      | ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)                        | Radioactive iodine |
| Busulfan (≥600 mg/m²)                                                          | Carboplatin cumulative dose ≤2 g/m²                                                    | CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)                 | Testicular radiation dose (<0.2 Gy) |
| Busulfan/cyclophosphamide                                                      | Cisplatin cumulative dose <400 mg/m²                                                  | COP (cyclophosphamide, vincristine, prednisone)                               |                   |
| CBV (cyclophosphamide, BCNU, etoposide), BCNU cumulative dose ≥300 mg/m²       | Testicular radiation dose (scatter from abdominal/pelvic radiation) (1–6 Gy)          | NOVP (mitoxantrone, vincristine, vinblastine, prednisone)                     |                   |
| ChlVPP (chlorambucil, vinblastine, prednisone, procarbazine)                   |                                                                                       | OPEA × 2 cycles (vincristine, etoposide, prednisone, doxorubicin)             |                   |
| ChlVPP/EVA (chlorambucil, vinblastine, prednisone, procarbazine, doxorubicin, vincristine, etoposide) |                                                                                       | Testicular radiation dose (0.2–0.7 Gy)                                       |                   |
| COPP × 6 cycles (cyclophosphamide, vincristine, procarbazine, prednisone)     |                                                                                       |                                                                               |                   |
| COPP/ABVD (cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine) |                                                                                       |                                                                               |                   |
| Cranial/brain radiation ≥240 Gy                                                |                                                                                       |                                                                               |                   |
| Cyclophosphamide ≥7.5 g/m²                                                     |                                                                                       |                                                                               |                   |
| Cyclophosphamide as bone marrow transplant conditioning                         |                                                                                       |                                                                               |                   |
| Cyclophosphamide (19 g/m²) plus total body irradiation                         |                                                                                       |                                                                               |                   |
| MOPP > 3 cycles (nitrogen mustard, vincristine, procarbazine, prednisone)     |                                                                                       |                                                                               |                   |
| MOPP/ABVD (nitrogen mustard, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine) |                                                                                       |                                                                               |                   |
| MVPP (nitrogen mustard, vinblastine, prednisone, procarbazine)                |                                                                                       |                                                                               |                   |
| Procarbazine cumulative dose ≥4 g/m²                                           |                                                                                       |                                                                               |                   |
| Testicular radiation dose >2.5 Gy in adults                                     |                                                                                       |                                                                               |                   |
| Testicular radiation dose ≥6 Gy in children                                    |                                                                                       |                                                                               |                   |
| Total body irradiation                                                         |                                                                                       |                                                                               |                   |
ICSI is available in most ART laboratories [39]. Protocols for freezing small samples (2 to 4 mm³) of immature human testicular tissue using dimethyl sulfoxide (DMSO) as the main cryoprotectant showed good structural integrity of testicular tubules, and pre-tubular and intra-tubular cells after thawing [11,40]. Xenotransplantation of cultured DMSO frozen SSCs from immature human testes showed the migration ability of SSCs to the base membrane of mouse seminiferous tubules without differentiation to mature germ cells [34]. The same cryopreservation method has been used for storing mice SSCs for longer than 14 years. Fertile offspring were derived after transplanting these long-term stored SSCs [41]. Our current testicular tissue banking protocol at Wake Forest Baptist Health for boys at risk of infertility indicates that, if testicular sperm are found, then half of the tissue will be frozen (Figure 2) in routinely used egg yolk-glycerol-based cryopreservation medium to preserve sperms for ICSI and the other half will be frozen to preserve the SSCs in DMSO-based medium for future culture and transplantation.

**Isolation and in vitro propagation of spermatogonial stem cells**

**Spermatogonial stem cell isolation**

The first successful isolation of human SSCs was reported from six infertile adult men in 2002 [42]. In that study, isolated human SSCs were able to colonize and survive for 6 months in mice recipient testes even after a freeze-thaw procedure. Numbers of colonized human SSCs in mouse seminiferous tubules were evaluated up to 6 months after transplantation. Observation of clusters of human SSCs about 1 month after transplantation suggested the proliferation of these cells in mouse testes. Human cells remained up to 6 months in mouse testes, although their numbers significantly decreased by 2 months after transplantation. No meiotic differentiation of human germ cells in mouse testes was observed [42]. Recently, in a study of prepubertal boys diagnosed with cancer, SSCs were isolated and demonstrated stem cell activity after xenotransplantation to mouse testes similar to that seen in human adult SSCs [43]. This study used biopsies from nine boys aged 2 to 10 years and a preliminary estimation indicated that spermatogonial cells comprised about 3% of the cell population from these biopsies [43]. The number of SSCs in the testis is very low. In mouse testis only 0.03% of germ cells and 1.25% of spermatogonial cells are estimated to be stem cells [44,45]. In contrast to rodents, human spermatogonial cells can be divided into two subgroups, AΔdark and AΔdark, according to their nuclear staining with hematoxylin after Bouin’s fixation [46]. AΔdark spermatogonia in normal circumstances are quiescent cells and are thought to be reserve (stem) cells [45]. Current SSC isolation methods are based on two-step enzymatic digestion [47]. Investigators have enriched human spermatogonial cells using magnetic activated cell sorting (MACS) with markers such as GFRA1⁺ [48], GPR125⁺ [49], SSEA4⁺ [50], and HLA-ABC⁻/CD9⁺ [51] or using fluorescence-activated cell sorting (FACS) by isolating EpCAM⁺/HLA-ABC⁻/CD49e⁻ cells [52]. Ideally, isolation of pure SSCs is expected, but no specific marker has been found to identify the stem cells in testis [53]. Finding suitable marker(s) is a formidable task [54].

**In vitro propagation**

In immature boys, the size of the testis is small with a rare population of SSCs; therefore, isolation of these cells from a
small testicular biopsy yields a very limited number of stem cells. Based on animal studies, SSC transplantation efficiency depends on the number of transplanted SSCs, with an almost linear correlation [55]. Therefore, increasing the number of SSCs in vitro is necessary before transplantation. Successful in vitro culturing of SSCs has been reported in several species, including mouse [56,57], rat [58], bovine [59], hamster [60], and dog [61]. Recently, in vitro propagation of human SSCs from both adult [62] and prepubertal [34] testes was established. In these systems, human SSCs are supported by a feeder layer from the same patients’ testicular somatic cells. Germ line stem cell clusters formed within 2 to 4 weeks of culture (Figure 3). Xenotransplantation of human testicular cells from different time points of in vitro culture into nude mice testes showed that human SSCs could be maintained in vitro for more than 15 weeks with a doubling time of 3 to 7 days [34,62]. Optimization of this culture system based on US Food and Drug Administration regulations and current good tissue practice requirements are imperative before use in a clinical application.

Figure 2 Testicular sperm viability after freeze and thaw. Live sperms were stained with Calcein (green fluorescent). (A) Bright field; (B) fluorescent; (C) merged. A LIVE/DEAD Sperm Viability Kit (L-7011 Invitrogen, Life Technologies Ltd, Paisley, UK) was used for staining thawed testicular sperms. Testicular tissue for research was obtained from transplant donors through the National Disease Research Interchange.

Figure 3 Germ line stem cells cluster in human testicular cell culture. The presence of these germ line clusters has been described previously [34,62]. (A) Bright field; (B) scanning electron microscopy. Testicular tissue for research was obtained from transplant donors through the National Disease Research Interchange.
Safety and technical issues of spermatogonial stem cell transplantation

Genetics and epigenetics stability
Harvesting testicular tissue via biopsy, freezing and thawing the tissue, and cell isolation and culturing are all processes that may affect the integrity of SSCs. Alterations in manipulated cells may occur in the genome, in the epigenome, or in both [63-65]. There are reports that show the genetic stability of other stem cell populations during in vitro culture [66,67]. Since SSCs are the cells that transmit genetic information to the next generations, concerns about SSC stability are much more important than those about somatic cells. A study on transplantation of isolated SSCs from C57Bl/WBRe donor mouse (without culturing) to the testes of W/Wv mice [68] showed normal development (length and weight) compared with controls for first and second generation offspring. DNA extracted from post-transplantation spermatozoa, liver, kidney and placenta revealed no differences in methylation patterns of genes for Igf2, Peg1 and a-Actin between offspring of transplanted and control mice [68]. Kanatsu-Shinohara and colleagues [69] showed that in vitro expansion of mouse SSCs over 24 months continued with normal karyotype and stable androgenetic imprinting. The offspring of recipient mice were fertile and also had a normal imprinting pattern. However, genetic alterations or epigenetic patterns of isolated and cultured human SSCs have not yet been determined.

Contamination with cancer cells
The most important concern regarding SSC autotransplantation is the risk of reintroducing malignant cells to the cancer survivor. This is very important in non-solid hematopoietic cancers, as malignant cells can migrate through the blood circulation and infiltrate the testis [70]. It has been demonstrated that intraluminal injection of as few as 20 leukemia cells into the testes of recipient rats could induce disease relapse in three out of five animals [71]. A few studies have tried to eliminate malignant cells from mouse, non-human primate and human testicular cell suspensions [52,72-75]. These studies used different surface markers for MACS or FACS of contaminating cells. Currently there is no specific marker for purifying SSCs [76] and these cells share several biomarkers with other stem cells and cancer cells, especially hematopoietic cells [77]; therefore, the sorting methods have not yielded tumor cell-free populations. The most recent study attempting to remove human leukemia cells from testicular cells using the markers EpCAM+/HLA-ABC+/CD49e− showed some progress [52]; however, the bioassay method used for post-sorting detection of leukemia cells was not sensitive enough (0.2% sensitivity) and the false negative rate was high (>60%) [52,75].

Using other detection methods with higher sensitivity, such as minimal residual disease PCR (up to 0.0001% sensitivity) [78] or tumor cell imaging (to detect as few as 3 to 10 cells) [79] are recommended. Our recently published pilot study using minimal residual disease PCR to track leukemia cells in a human SSC in vitro propagation system showed leukemias cells were eliminated after 26 days of co-culturing with spermatogonial cells [80].

Spermatogonial stem cell injection
A mouse model for injection of SSCs into the testis is possible with the microinjection of the SSCs into the seminiferous tubules, into the rete testis, or into the efferent duct [81]. However, in larger animals like bovine, monkey and even human cadaver, studies have shown that injection of SSCs into the seminiferous tubules or the efferent duct was not successful [82]. This is because of high resistance of the lamina propria and coiled seminiferous tubules in larger animals. The most promising models for SSC injection into human testis is ultrasound-guided injection into the rete testis [82,83]. In the most recent study on autopsied human testes, injecting 8 to 16 million cells in a volume of 800 to 1,400 μl via a 23 gauge needle could fill up to 40% of the seminiferous tubules in 1 to 2 minutes [83]. There is only one reported clinical trial of SSC autotransplantation, in seven cancer survivors [84], but the details of this study and patient follow-up data have not been published. Further investigation is necessary to optimize the injection procedure as well as compare ultrasound-guided versus open surgery for SSC transplantation.

Points of view of patients and their families
It is important to understand how patients and their families feel about fertility preservation and testicular tissue banking. Psychosocial studies clearly demonstrate a high incidence of negative reactions to infertility and its negative effect on overall life satisfaction and well-being [85]. The main target groups for testicular tissue cryopreservation for future SSC autotransplantation are children, which presents difficulties for discussion of future reproduction and family planning. Childhood cancer survivors who transit into adulthood express concerns about fertility and fathering children [86]. At least half of the parents of boys who suffer from cancer agree with performing testicular biopsy to preserve SSCs [35,87,88]. Parents choose fertility preservation even if the chance of infertility is low (≤20%) and the success rate of future SSCs transplantation will also be low (≤20%) [88]; these findings show the great importance of fertility preservation for families.
Follow-up after spermatogonial stem cell transplantation

Both childhood and adult cancer survivors are interested in understanding the risks of passing on genetic damage capable of causing adverse outcomes in their children [89]. Reviewing a cohort of 8,670 children born between 1994 and 2004 with a paternal history of cancer versus 17,690,795 children without a paternal history of cancer showed a higher incidence of major congenital abnormalities in the offspring of male cancer survivors (3.7 out of 100) than in those of fathers with no history of cancer (3.2 out of 100) [90]. Around 5% of children (508 out of 8,670) were conceived using ART, either in vitro fertilization (5%) or ICSI (95%), with the higher risk of abnormalities with in vitro fertilization (two times more) compared to ICSI or natural conception [90]. Previous studies have shown no significant differences in the outcome of pregnancy in cancer survivors [91,92]. However, ICSI (when it is required) and prenatal diagnosis tests (for example, amniocentesis) during pregnancy in cancer survivors may overcome this small risk.

As clinical trials of SSC autotransplantation are initiated, it is necessary to monitor the health of recipient men. Like other ART treatments, pregnancy and the offspring should be followed for any major abnormalities.

Conclusion

SCCs are germ line stem cells that reside in the basement membrane of the seminiferous tubule in the testis. They are the foundation of spermatogenesis for the production of sperm after puberty. In 1994 Brinster’s group [6] reported a SSC assay in mice that shows the ability of these cells to generate a colony of spermatogenesis after transplantation in the seminiferous tubules of a recipient male. Since then, researchers in the field of male infertility have searched for new clinical tools to help more men who suffer from primary testicular failure. Immature boys at risk of losing their SSCs, mostly cancer patients, are the main target group that may benefit from testicular tissue cryopreservation and SSC autotransplantation. Progress in the field of SSC transplantation in animal studies, including non-human primates, has been shown. Effective freezing methods for adult and prepubertal testicular tissue are available and recently in vitro propagation of human SSCs with the ability to colonize the basement membrane of testes has been established. Therefore, translation of SSC autotransplantation to humans is expected to be possible in the near future. The families of prepubertal and adolescent male patients are eagerly awaiting fertility preservation by means of testicular tissue banking and utilization in future clinical applications. Simultaneous to the ongoing research on safety and technical issues of human SSC autotransplantation, it is necessary to counsel parents and the boys at risk of infertility on the possibility of cryopreserving a small testis biopsy in experimental SSC banking.

Note: This article is part of a thematic series on Stem cells in genitourinary regeneration edited by John Jackson. Other articles in the series can be found online at http://stemcellres.com/series/genitourinary.

Abbreviations

ART: Assisted reproductive technology; DMSO: Dimethyl sulfoxide; FACS: Fluorescence-activated cell sorting; ICSI: Intracytoplasmic sperm injection; KS: Klinefelter syndrome; MACS: Magnetic activated cell sorting; PCR: Polymerase chain reaction; SSC: Spermatogonial stem cell.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

We would like to thank Drs John D Jackson and Sean V Murphy for editorial assistance. We acknowledge use of tissues procured by the National Disease Research Interchange (NDRI) with support from NIH grant SU42RR006042. This work was supported by Erret-Fisher Foundation grant GTS 3679.

Author details

1Wake Forest Institute of Regenerative Medicine (WFIRM), Wake Forest School of Medicine, Winston-Salem, North Carolina 27101, USA.
2Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran 1177-19615, Iran.
3Department of Urology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27101, USA.

Published: 28 May 2014

References

1. Krausz C. Male infertility: pathogenesis and clinical diagnosis. Best Pract Res Clin Endocrinol Metab 2011, 25:271–285.
2. Ruestow EG: Images and ideas: Leeuwenhoek’s perception of the spermatozoa. J Hist Biol 1983, 16:185–224.
3. Palermo G, Jons H, Devoege P, Van Steenberghen AC: Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992, 340:17–18.
4. Anawalt BD: Approach to male infertility and induction of spermatogenesis. J Clin Endocrinol Metab 2013, 98:3532–3542.
5. Huckins C: The spermatogonial stem cell population in adult rats. Their morphology, proliferation and maturation. Anat Rec 1971, 169:533–557.
6. Brinster RL, Zimmermann JW: Spermatogenesis following male germ-cell transplantation. Proc Natl Acad Sci U S A 1994, 91:11298–11302.
7. Hermann BP, Sukhwani M, Winkler F, Pascarella JN, Petters KA, Sheng Y, Valli H, Lienesch M, Volk A, Cooper DK, Thomson AW, Kiss JE, Penedo MC, Schatten GP, Mitalipov S, Orwig K: Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell 2012, 11:715–726.
8. O’Connor-Von S: Coping with cancer: a web-based educational program for early and middle adolescents. J Pediatr Oncol Nurs 2009, 26:230–241.
9. Agarwal A, Allamaneni SS: Disruption of spermatogenesis by the cancer disease process. J Natl Cancer Inst Monogr 2005, 34:9–12.
10. Meistrich ML: Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril 2013, 100:1189–1186.
11. Wyns C, Van Langendonckt A, Wese FX, Donnez J, Curaba M: Long-term spermatogonial survival in cryopreserved and xenografted immature human testicular tissue. Hum Reprod 2008, 23:2402–2414.
12. Panagia R, Nital M: Morphological and histometric study of human spermatogonia from birth to the onset of puberty. J Anat 1984, 139:525–552.
13. Wallace WH, Anderson RA, Irvine DS: Fertility preservation for young
patients with cancer: who is at risk and what can be offered?
Lancet Oncol 2005, 6:209–218.

14. Wyns C, Curaba M, Pett S, Vanabele S, Laurent P, Wese JF, Donez J:
Management of fertility preservation in prepubertal patients: 5 years'
experience at the Catholic University of Louvain. Hum Reprod 2001, 16:737–747.

15. Feldschihr J, Brasseil J, Durso N, Levine A: Successful sperm storage for
28 years. Fertil Steril 2005, 84:1017.

16. Ansari P, Chiordi S, Spinelli S, Costa M, Conte N, Copello F, Bacigalupo A:
Semen analysis following allogeneic bone marrow transplantation.
Additional data for evidence-based counselling. Bone Marrow Transplant 2002, 30:447–451.

17. Berthaut J, Guignegoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D,
Galactéros F, Ancel PR, Kunstmann JM, Levy L, Jouanneau P, Grot R, Mandelbaum J:
Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of
human males. Haematologica 2008, 93:998–993.

18. Oktay K, Oktay O: Fertility preservation medicine: a new field in the care
of young cancer survivors. Pediatr Blood Cancer 2009, 53:267–273.

19. David J, Vouyiouka O, Ansell BM, Hall A, Woo P: Aplasia lymphoidis in juvenil
arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993, 11:85–90.

20. Bojesen AE, Juul S, Gravholt CH: Prenatal and postnatal prevalence of
Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2010, 95:822–626.

21. Hofheinz SE, Ikotok AE, Kipp BR, Dawson DE, Van Dyke DL: Clinical diagnostic
testing for the cytogenetic and molecular causes of male infertility: the Mayo
Clinic experience. J Ass Reprod Genet 2001, 18:1091–1098.

22. Aksglaede L, Juul A: Testicular function and fertility in men with
Klinefelter syndrome: a review. Eur J Endocrinol 2013, 168:677–679.

23. Neumaier M, Böckler T, Glode M, Hadziselimovic F: Testicular volume
measured by ultrasonography in a normal population from infancy to
adulthood. J Urol 2007, 178:576–581.

24. Aksglaede L, Juul A: Testicular microlithiasis and antisperm antibodies following testicular biopsy
in young men recently diagnosed with cancer: a report of acceptability and safety. Hum Reprod 2009, 24:507–513.

25. Mehta A, Bolyakov A, Roosma J, Schlegel PN, Paduch DA: Management of fertility preservation in prepubertal
patients: 5 years experience. Hum Reprod 2011, 26:1395–1401.

26. Meij-de Vries A, de Waal HA D-v: Normative values for testicular volume
in infants, children and adults. Scand J Urol Nephrol Suppl 2005, 220:76–80.

27. Schmidt RA, Hentschel B, Friedrich M, Jahnhaupten K, Hovatta O:
Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer
treatment. Hum Reprod 2007, 22:1394–1393.

28. Hadziselimovic F, Hoecht B: Testicular histology related to fertility
following testicular biopsy in young cancer survivors. Pathol Res Pract 2009, 205:191–200.

29. Tegelenbosch RA, de Rooij DG: A quantitative study of spermatogonial multiplication and stem cell renewal in the
C3Hf101 F1 hybrid mouse. Hum Reprod 1993, 9:203–9.

30. Aponte PM, van Bragg GP, de Rooij DG, van Pelt AM: Fertility preservatio
steem cells: characteristics and experimental possibilities. J Assist Reprod Genet 2005, 22:127–727.

31. Clermont Y: Spermatogenesis in man. A study of the spermatogonial
population. Fertil Steril 1966, 17:705–721.

32. van Pelt AM, Morena AR, van DesselEmiliann AM, Botani C, Gaemers IC,
de Rooij DG: Spermatogonia: Isolation of the synchronized A spermatogonia from adult vitamin A-deficient rat testes. Biol Reprod 1996, 55:349–444.

33. Kassee M, Ehrmcke J, Schlatt S: Efficient enrichment of undifferentiated GFR alpha 1+ spermatogonia from immature rat testis by magnetic activated cell sorting. Cell Tissue Res 2009, 337:177–183.

34. He Z, Kokkinaki M, Jiang J, Dobrinski I, Dym M: Isolation, characterization,
and culture of human spermatogonia. Biol Reprod 2010, 82:363–372.

35. Izbay F, Wond J, Maki C, Pacchiarotti J, Rronton K, Yuan C,
Greilach S, Zhao H, Chow M, Chow YC, Rao J, Barritt J, Bar-Chama N,
Copperman A: Identification and characterization of repopulating spermatogonial stem cells from the adult human testes. Hum Reprod 2011, 26:1396–1306.

36. Zohni K, Zhang X, Tan SL, Chen P, Nagano M: CD9 is expressed on human male germ cells that have a long-term repopulation potential after transplantation into mouse testes. Biol Reprod 2012, 87:37.

37. Dobrinski I, Ogawa T, Avarbock MR, Dobrinski I: Cryopreservation of intact
testicular tissue from boys with cryptorchidism. J Assist Reprod Genet 2006, 23:494–491.

38. Patel PP, Kolon TF, Huff DS, Carr MC, Zaidi SC, Canning DA, Snyder HM 3rd:
Testicular microthiliosis and antisperm antibodies following testicular biopsy
in boys with cryptorchidism. J Urol 2007, 177:2006–210. discussion 2010.

39. Greilach S, Zhao H, Chow M, Chow YC, Rao J, Barritt J, Bar-Chama N, Copperman A: Identification and characterization of repopulating spermatogonial stem cells from the adult human testes. Hum Reprod 2011, 26:1396–1306.

40. Zohni K, Zhang X, Tan SL, Chen P, Nagano M: CD9 is expressed on human male germ cells that have a long-term repopulation potential after transplantation into mouse testes. Biol Reprod 2012, 87:37.

41. Deyan F, Wond J, Maki C, Pacchiarotti J, Rronton K, Yuan C,
Greilach S, Zhao H, Chow M, Chow YC, Rao J, Barritt J, Bar-Chama N,
Copperman A: Identification and characterization of repopulating spermatogonial stem cells from the adult human testes. Hum Reprod 2011, 26:1396–1306.

42. Zohni K, Zhang X, Tan SL, Chen P, Nagano M: CD9 is expressed on human male germ cells that have a long-term repopulation potential after transplantation into mouse testes. Biol Reprod 2012, 87:37.

43. Crabebe E, Verheyen G, Tournaye H, Van Steirteghem A: Eliminating malignant contamination from therapeutic human stem cells: from mice to men. Science 2007, 316:404–405.

44. Kanatsu-Shinohara M, Shinohara T: Spermatogonial stem cell regeneration and development. Annu Rev Cell Dev Biol 2013, 29:163–187.

45. Dobrinski I, Ogawa T, Avarbock MR, Brinster RL: Computer assisted image analysis to assess colonization of recipient seminiferous tubules by spermatogonial stem cells from transgenic donor mice. Mol Reprod Dev 1999, 53:142–148.

46. Kanatsu-Shinohara M, Miki H, Inoue K, Ogunuki T, Toyokawa S, Ogura A, Shinohara T: Long-term culture of mouse male germ line stem cells under serum- or feeder-free conditions. Biol Reprod 2005, 72:895–991.

47. Kanatsu-Shinohara M, Ogunuki T, Inoue K, Miki H, Ogura A, Toyokawa S, Shinohara T: Long-term proliferation in culture and germline transmission of mouse male germ line stem cells. Biol Reprod 2003, 69:512–516.

48. Hamra FK, Chapman KM, Nguyen DM, Williams-Stephens AA, Hammer RE,
Garbers DL: Self renewal, expansion, and transfection of rat spermatogonial stem cells in culture. Proc Natl Acad Sci U S A 2005, 102:17430–17435.

49. Aponte PM, Soda T, Teerds KJ, Mizrazi SC, van de Kant HJ, de Rooij DG:
Propagation of bovine spermatogonial stem cells in vitro. Reproduction 2003, 136:593–597.
lymphoblastic leukemia cells from human testicular cell cultures: a pilot study. Fertil Steril 2014, 101:1072–1078.
80. Ogawa T, Areczagha JM, Avarbock MR, Brinster RL: Transplantation of testis germinal cells into mouse seminiferous tubules. Int J Dev Biol 1997, 41:111–122.
81. Schmitt S, Rosegen K, Weinbauer GF, Rolf C, Brook PF, Nieschlag E: Germ cell transfer into rat, bovine, monkey and human testes. Hum Reprod 1999, 14:144–150.
82. Fares K, Tournaye H, Goethals L, Lahoutte T, Hoorens A, Goossens E: Testicular cell transplantation into the human testes. Fertil Steril 2013, 100:981–988 e984.
83. Radford JA: Is prevention of sterility possible in men? Ann Oncol 2000, 11(Suppl 3):173–174.
84. Boivin J, Takedjian J, Braverman A: The fertility quality of life (FertiQoL) tool: development and general psychometric properties. Hum Reprod 2011, 26:2084–2091.
85. Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK: Fertility issues for young adult survivors of childhood cancer. Psycho-Oncology 2004, 13:689–699.
86. van den Berg H, Repping S, van der Veen F: Parental desire and acceptability of spermatogonial stem cell cryopreservation in boys with cancer. Hum Reprod 2007, 22:594–597.
87. Sadri-Ardekani H, Akhondi MM, Vossough P, Maleki H, Sedighnejad S, Kamali K, Ghorbani M, van Wely M, van der Veen F, Repping S: Parental attitudes toward fertility preservation in boys with cancer: context of different risk levels of infertility and success rates of fertility restoration. Fertil Steril 2013, 99:706–802.
88. Signorello LB, Friedman DL, Boice JD Jr: Congenital abnormalities: a legacy of cancer treatment? J Natl Cancer Inst 2011, 103:358–359.
89. Stahl O, Boyd GA, Hiwercz H, Lindholm M, Jensen A, Kjaere SK, Anderson H, Cavallin-Stahl E, Rylander L: Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish nationwide registries. J Natl Cancer Inst 2011, 103:398–406.
90. Byrne J, Rasmussen SA, Steinhorn SR, Connolly RR, Myers MH, Lynch CF, Flannery J, Austin DF, Holmes FF, Holmes GE, Strong LC, Mulvihill JJ: Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Ann J Hum Genet 1998, 62:45–52.
91. Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL, Mineau GP, Hamre MR, Severson RK, Dews-Botsch C, Mueller BA: Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med 2009, 163:887–894.